Acknowledgements

The 5th International Workshop on Waldenström’s macroglobulinemia was made possible through the kind and generous unrestricted grants or gifts from the following sponsors:

Peter and Helen Bing Fund for Waldenström’s Macroglobulinemia

Karen Lee Sobol Foundation

Bailey Family Foundation for Waldenström’s Macroglobulinemia

Linda and Edward Nelson Fund for Waldenström’s Macroglobulinemia
Welcome to Stockholm, Sweden!

It is with great pleasure that we welcome you to Stockholm and the 5th International Workshop on Waldenström’s Macroglobulinemia (IWWM5). The IWWM5 promises to be a very exciting meeting, and reflects the continued growth in investigators working on the genetic basis, pathogenesis, and treatment of WM. Since the IWWM began in 2000, the number of participating investigators has steadily grown, as have also the number of WM related publications including those arising from the IWWM which have been published in *Blood, Clinical Lymphoma Myeloma, Haematologica, Journal of Clinical Oncology and Seminars in Oncology*.

We are particularly excited to host this workshop in the native land of Dr. Jan Waldenström, whose memorable career was marked by the recognition of several diseases, including the eponymous macroglobulinemia first described by him sixty-five years ago in *Acta Medica Scandinavica*. As part of the IWWM5, a special tribute in honor of the life of Dr. Jan Waldenström will be hosted in the Nobel Hall of Stockholm City Hall.

We hope the IWWM5 will enrich each attendees understanding of Waldenström’s Macroglobulinemia, and help foster discoveries leading to its cure.

*Eva Kimby M.D., Ph.D.*  
*Sweden*  

*Steve Treon M.D., Ph.D.*  
*USA*
Wednesday, October 15, 2008  Sheraton Stockholm
Registration and Welcome Dinner Reception

3:00-6:00 PM Registration  Conference Hall Lobby
6:00 PM  Welcome Dinner
6:30 PM  Christopher Patterson (USA)  Program Review

Thursday, October 16, 2008  Sheraton Stockholm
Workshop Program

7:00-8:00 AM  
Breakfast and Registration  Conference Hall Lobby

Session I  Incidence and Predispositions to WM  
Chairs: Dr. Björkholm (Sweden) and Dr. McMaster (USA)

8:00 AM  Dr. Wang (USA)  Trend and Geographical Variations of WM incidence in USA.
8:15 AM  Dr. Iwanaga (Japan)  Prevalence of MGUS and WM in Japan.
8:30 AM  Dr. Kyle (USA)  Natural History of IgM, MGUS and WM.
8:45 AM  Dr. Ögmundsdóttir (Iceland)  Familial predisposition to MGUS, MM, WM.
9:00 AM  Dr. McMaster (USA)  Precursor disorders in WM.
9:15 AM  Dr. Kristinsson (Sweden)  Risk lymphoproliferative disorders in relatives of LPL patients.
9:30 AM  Dr. Hunter (USA)  Report from Familial Registry Studies in WM.
9:45 AM  Panel Discussion  All Session I Speakers.
10:15-10:30 AM  Session Break and Refreshments.
Session II  Genetic Basis & Pathogenesis of WM and IgM Related Disorders  
Chairs: Dr. Garcia-Sánz (Spain) and Dr Pilarski (Canada)

10:30 AM  Dr. Pilarski (Canada)  Origin of malignant clone in WM.
10:45 AM  Dr. Sahota (England)  CD27 and defining B-cell memory origins in WM.
11:00 AM  Dr. Nguyen-Khac (France)  Cytogenetic abnormalities in untreated WM patients: Trisomy 4 prevalence.
11:15 AM  Dr. Eurelings (Netherlands)  Cytogenetic abnormalities in IgM Related Disorders.
11:30 AM  Dr. Braggio (USA)  TRAF3 abnormalities in WM.
11:45 AM  Panel Discussion  All Session II Speakers.
12:15-1:15 PM  Session Break and Lunch.

Session III  Genetic Basis & Pathogenesis of WM and IgM Related Disorders  
Chairs: Dr. Sahota (England) and Dr Ocio (Spain)

1:15 PM  Dr. Garcia-Sánz (Spain)  Molecular characterizations of Ig rearrangements in WM.
1:30 PM  Dr. Adamia (USA)  MicroRNA studies in WM.
1:45 PM  Dr. Xu (USA)  Hypermethylation Studies of Tumor Suppressor Genes in WM.
2:00 PM  Dr. Ansell (USA)  Roles of CCL5 and IL6 in Biology of WM
2:15 PM  Dr. Giordano (USA)  Role of Hepatitis C in WM.
2:30 PM  Dr. Landgren (USA)  Chronic immune stimulation and subsequent WM.
2:45 PM  Panel Discussion  All Session III Speakers.
3:15-3:30 PM  Session Break and Refreshments.
**5th International Workshop on Waldenström’s Macroglobulinemia**  
**October 15-19, 2008**  
**Stockholm, Sweden**

### Session IV Micro-environment and Immune Regulation in WM

Chair: Dr. Joshua (Australia) and Dr. Munshi (USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 PM</td>
<td>Dr. Hatjiharissi (Greece)</td>
<td>GEP of WM and Microenvironment</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Dr. Terpos (Greece)</td>
<td>Angiogenesis signaling in WM.</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Dr. Ocio (Spain)</td>
<td>Immunophenotypic comparisons of IgM, MGUS and WM.</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>Dr. Munshi (USA)</td>
<td>Abnormal cytokine signaling in WM</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Dr. Joshua (Australia)</td>
<td>T-cell immunity in WM &amp; MM.</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Panel Discussion</td>
<td>All Session IV Speakers.</td>
</tr>
<tr>
<td>5:15 PM</td>
<td>Dr. Kimby (Sweden)</td>
<td>Day Summary and Adjournment.</td>
</tr>
<tr>
<td></td>
<td>Dr. Treon (USA)</td>
<td></td>
</tr>
</tbody>
</table>

### Thursday, October 16, 2008 Vasa Museum

**Opening Ceremonies**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 PM</td>
<td>Sheraton Stockholm</td>
<td>Buses depart to Vasa Museum.</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Vasa Museum</td>
<td>Welcome Reception and Tours.</td>
</tr>
<tr>
<td>8:00 PM</td>
<td>Dr. Kimby (Sweden)</td>
<td>Welcome Address.</td>
</tr>
<tr>
<td>8:00 PM</td>
<td>Dr. Treon (USA)</td>
<td>Welcome Address.</td>
</tr>
<tr>
<td>8:15 PM</td>
<td>J. May (USA)</td>
<td>IWMF President’s Address.</td>
</tr>
<tr>
<td>8:30 PM</td>
<td>K. Lee Sobol (USA)</td>
<td>Special Guest, Author of “Twelve Weeks”.</td>
</tr>
<tr>
<td>8:45 PM</td>
<td>Dr. Dunsire (USA)</td>
<td>President, CEO, Millennium Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>9:00 PM</td>
<td>S. Barer (USA)</td>
<td>Chair, CEO, Celgene Corporation.</td>
</tr>
<tr>
<td>9:15 PM</td>
<td>Dr. Kyle (USA)</td>
<td>Presentation of the Robert A. Kyle Award.</td>
</tr>
<tr>
<td>9:30 PM</td>
<td>Award Winner</td>
<td>Recipient Remarks.</td>
</tr>
<tr>
<td>10:30 PM</td>
<td>Vasa Museum</td>
<td>Buses depart to Sheraton Stockholm.</td>
</tr>
</tbody>
</table>
Friday, October 17, 2008
Sheraton Stockholm

Workshop Program

7:00-8:00 AM
Breakfast and Registration
Conference Hall Lobby

Session V  Prognostic, Predictive and Response Markers in WM
Chair: Dr. Owen (England) and Dr. Morel (France)

8:00 AM  Dr. Morel (France)  International WM Prognostic Index Project.
8:15 AM  Dr. Chang (Canada)  Role of 6q deletions as a prognostic marker in WM.
8:30 AM  Dr. Feuillard (France)  Plasma cell differentiation in indolent lymphomas originated from marginal zones.
8:45 AM  Dr. Kastritis (Greece)  Prognostication in young and elderly patients with WM.
9:00 AM  Dr. Owen (England)  Complexities of assessing response in WM.
9:15 AM  Dr. Yang (USA)  Soluble CD27 as a novel marker of disease in WM.
9:30 AM  Panel Discussion  All Session V Speakers.
10:00-10:15 AM  Session Break and Refreshments.
### Session VI Treatment of Waldenström’s Macroglobulinemia

**Chairs:** Dr. Morra (Italy) and Dr. Rohatiner (England)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 AM</td>
<td>Dr. Dimopoulos (Greece)</td>
<td>Rituximab based therapies in WM.</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Dr. Ghielmini (Switzerland)</td>
<td>Maintenance Rituximab in indolent NHL.</td>
</tr>
<tr>
<td>10:45 AM</td>
<td>Dr. Morra (Italy)</td>
<td>Fludarabine based therapies in WM.</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Dr. Branagan (USA)</td>
<td>Long term outcomes of Fludarabine and Rituximab in WM.</td>
</tr>
<tr>
<td>11:15 AM</td>
<td>Dr. Chen (Canada)</td>
<td>Bortezomib in relapsed/refractory WM.</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Dr. Rohatiner (England)</td>
<td>Weekly versus twice weekly Bortezomib Combinations in WM.</td>
</tr>
<tr>
<td>11:45 AM</td>
<td>Dr. Treon (USA)</td>
<td>Primary Therapy of WM with Bortezomib based Therapy.</td>
</tr>
<tr>
<td>12:00 AM</td>
<td>Panel Discussion</td>
<td>All Session VI Speakers.</td>
</tr>
<tr>
<td>12:30 PM</td>
<td></td>
<td>Session Break and Lunch.</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Dr. O’Connor (USA)</td>
<td>Special Guest Lecturer: &quot;The Emerging Role of Histone Deacetylase Inhibitors in WM&quot;.</td>
</tr>
</tbody>
</table>
Session VII  Novel Agents for Treatment of WM  
Chairs: Dr. Dimopoulos (Greece) and Dr. Leblond (France)

1:30 PM  Dr. Buske (Germany)  CHOP vs. CHOP-R in WM.
1:45 PM  Dr. Rummel (Germany)  Bendamustine and Rituximab versus CHOP-R in WM.
2:00 PM  Dr. Ghobrial (USA)  Akt and MTOR inhibitors in WM.
2:15 PM  Dr. Grewal (USA)  Targeting CD70 in WM.
2:30 PM  Dr. Advani (USA)  Targeting CD40 in WM.
2:45 PM  Dr. Roccaro (USA)  Novel proteosome inhibitors in WM.

3:00 PM  Panel Discussion  All Session VII Speakers.

3:15-3:45 PM  Session Break and Refreshments.

3:45-4:15 PM  Special Guest Lecturer:  
Dr. Anderson (USA)  “Applying the Lessons of MM Therapy to WM”.

Consensus Panel Session I  
Chairs: Dr. McMaster (USA) and Dr Pilarski (Canada)

4:15-6:00 PM  Basic and Translational Study Priorities in WM.

6:00 PM  Dr. Kimby (Sweden)  Day Summary and Adjournment.
Dr. Treon (USA)
Friday, October 17, 2008
Nobel Museum, Gamla Stan (Old City)
Faculty and YIA Dinner Reception and Poster Presentations

7:00-8:00 PM
Dinner Reception and YIA Recipient Poster Presentations

8:15 PM
Professor Anders Bárany (Sweden)
Deputy Director of the Nobel Museum and Secretary of the Nobel Committee for
Physics of the Royal Swedish academy of Sciences.
"History of Alfred Nobel and the Nobel Prize"

8:30 PM
Professor Ken Anderson (USA)
Kraft Professor of Medicine, Harvard Medical School, Chief Hematologic Neoplasias,
Dana Farber Cancer Institute.
Waldenström’s Award Winner (2005)
"Are Innovations in Plasma Cell Disorders Worthy of a Nobel Prize?"

8:45 PM
Professor Bart Barlogie (USA)
Professor of Medicine, Head of Myeloma Institute, University of Arkansas.
Waldenström’s Award Winner (1999)
"Is WM the next plasma cell disorder we should stop calling incurable?"

9:00 PM
Drs. Eva Kimby and Steve Treon (Sweden, USA)
Presentation of Young Investigator Awards
Closing Comments
5th International Workshop on Waldenström’s Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden

2008 YIA Recipients

Poster 1: Xiaoying Jia (USA)
“*The Novel Hydroxamic Acid-Derived HDAC Inhibitor, LBH589, Induces In Vitro Antitumor Activity in Waldenström’s Macroglobulinemia*”

Poster 2: Jenny Sun (USA)
“*HDAC inhibitors: Epigenetic targeted therapies as monotherapy and combined treatments in WM*”

Poster 3: Hai T. Ngo (USA)
“*SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenström’s macroglobulinemia*”

Poster 4: Bénédicte Hivert (France)
“*Acquired von Willebrand factor abnormalities in Waldenström’s Macroglobulinemia*”

Poster 5: Stéphanie Poulain (France)
“*Is SDF1(-801 GA) polymorphism a new genetic prognostic for survival after treatment initiation in Waldenström’s macroglobulinemia (WM)*”

Poster 6: Laurent Vallat (France)
“*Toward a Proteomic Specific Waldenström’s macroglobulinemia Entity*”

Poster 7: Thea Ioakimidis (USA)
“*Comparative Outcomes following CP-R, CVP-R and CHOP-R in patients with Waldenström’s Macroglobulinemia*”

Poster 8: Stefan Peinert (Australia)
“*Fludarabine based combinations are highly effective as first-line or salvage treatment for patients with Waldenström’s Macroglobulinemia*”
5th International Workshop on Waldenström’s Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden

Saturday, October 18, 2008                  Sheraton Stockholm
7:00 AM-8:00 AM                           Conference Hall Lobby
Breakfast and Registration               

Session VIII  Transplant Therapy in WM
Chairs: Dr. Maloney (USA) and Dr Barlogie (USA)

8:00 AM       Dr. Barlogie (USA)                  High Dose Therapy in WM.
8:15 AM       Dr. Kyriakou (England)             EBMT Update of Transplant Experience in WM.
8:30 AM       Dr. Maloney (USA)                  GVWM following Mini-Allogeneic Transplants in WM.
8:45 AM       Dr. Gertz (USA)                    Transplants for the management of amyloidosis in WM.
9:00 AM       Panel Discussion                   All Session VIII Speakers.

Session IX  Therapy Related Complications in WM
Chairs: Dr. Kyle (USA) and Dr. Fermand (France)

9:30 AM       Dr. Thomas (USA)                   Stem cell collection in WM.
9:45 AM       Dr. LeBlond (France)              Disease Transformation and Development in MDS/AML. following nucleoside analogues in WM.
10:00 AM      Dr. Leleu (France)                Long term complications of nucleoside analogue therapy in WM.
10:15 AM      Dr. Seymour (Autralia)            Pros and Cons of nucleoside analogues.
10:30 AM      Panel Discussion                   All Session XI Speakers.
11:00-11:15 AM Session Break and Refreshments.
Session X Disease-Related Morbidities in WM
Chairs: Dr. Merlini (Italy) and Dr. Stone (USA)

11:15 AM Dr. Hochberg (USA) Diagnosis and Management of Bing-Neel Syndrome.
11:30 AM Dr. Nobile-Orazio (Italy) Antigenic determinants of paraprotein related neuropathies in WM.
11:45 AM Dr. Levine (USA) Treatment of IgM related neuropathy.
12:00 PM Dr. Fermand (France) Cutaneous manifestations of WM.
12:15 PM Dr. Berentsen (Norway) Cold Agglutinin mediated AIHA in WM.
12:30 PM Dr. Stone (USA) Hyperviscosity Syndrome and Cryoglobulinemia.
12:45 PM Dr. Menke (Switzerland) Hyperviscosity related retinopathy in WM.

1:00 PM Panel Discussions All Session X Speakers.
1:30-2:30 PM Session Break and Lunch.
2:00-2:30 PM Special Guest Speaker: Dr. Merlini (Italy) “Biology and Therapy of Amyloidosis associated with IgM monoclonal protein”

Consensus Panel Session II
Chairs: Dr. Dimopoulos (Greece) and Dr Treon (USA)

2:30-4:00 PM Treatment Options and Clinical Trial Priorities in WM.
4:00 PM Dr. Kimby (Sweden) Day Summary and Adjournment.
Dr. Treon (USA)
**Saturday, October 18, 2008**

### Closing Ceremonies

**Stockholm City Hall/Nobel Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 PM</td>
<td>Faculty and YIA Group Photo Session</td>
<td>Blue Room/Nobel Hall.</td>
</tr>
<tr>
<td>7:30 PM</td>
<td>Welcome Reception and Chorus Serenade</td>
<td>Golden Room Balcony.</td>
</tr>
<tr>
<td>8:00 PM</td>
<td>Dinner Reception</td>
<td>Golden Room/Nobel Hall.</td>
</tr>
<tr>
<td>8:15 PM</td>
<td>Mr. Bo Aurehl (Sweden)</td>
<td>History of the Nobel Hall.</td>
</tr>
<tr>
<td>8:30 PM</td>
<td>Dr. P. Bing (USA)</td>
<td>Former Chair, and Trustee, Stanford University.</td>
</tr>
<tr>
<td>8:40 PM</td>
<td>Mrs. Harriet Fulbright (USA)</td>
<td>Former Chair, U.S. National Endowment for Arts, Humanities; President, Fulbright Foundation.</td>
</tr>
<tr>
<td>9:00 PM</td>
<td>Dr. Kimby (Sweden)</td>
<td>Tribute to Jan Waldenström.</td>
</tr>
<tr>
<td>9:10 PM</td>
<td>Dr. A. Waldenström (Sweden)</td>
<td></td>
</tr>
<tr>
<td>9:20 PM</td>
<td>Dr. U. Ringborg (Sweden)</td>
<td></td>
</tr>
<tr>
<td>9:30 PM</td>
<td>Dr. G. Merlini (Italy)</td>
<td></td>
</tr>
<tr>
<td>9:40 PM</td>
<td>Dr. Treon (USA)</td>
<td>Presentation of Waldenström Awards.</td>
</tr>
<tr>
<td>10:00 PM</td>
<td>Chairs Closing Remarks</td>
<td></td>
</tr>
</tbody>
</table>
5th International Workshop on Waldenström’s Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden

Sunday, October 19, 2008 Sheraton Stockholm
IWMF European WM Patient and Physician Forum

Moderators: Drs. Eva Kimby (Sweden) and Véronique LeBlond (France).

9:00 AM Dr. Kyle (USA) Diagnosis and Criteria to Treat WM.
9:30 AM Dr. Treon (USA) Consensus Recommendations for Treatment of WM.
10:00 AM Dr. LeBlond (France) Weighing Long Term Consequences in Treatment Decisions.
10:30 AM Dr. Kimby (Sweden) Response Criteria in WM.
10:30-12:00 All Session Speakers Panel Discussions.
12:00-1:15 PM Session Break and Luncheon.
1:15-2:00 PM
  Ms. Lynn Paul (USA) Patient Guest Speakers
  Mr. Edward Saltzman (USA)
  Mrs. Karen Lee Sobol (USA)
2:00-5:00 PM
  U.S.-European IWMF Sponsored Patient Meeting
CME Accreditation.

The 5th International Workshop on Waldenström's Macroglobulinemia is accredited by EXCEL Continuing Education in conformance with the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and nurses. This activity is designated for a maximum of 29.00 AMA PRA Category 1 Credits. Physicians and nurses attending this event should only claim credit commensurate with the extent of their participation in the activity.

Disclosures.

In accordance with ACCME standards, all speakers were required to provide disclosure of affiliations and/or financial interests with commercial organizations involved with products to which they may refer to during their presentations. Presenters who have made a disclosure are as follows:

Kenneth C. Anderson, MD
Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Inc.

Bart Barlogie, MD, PhD
Celgene Corporation, Millennium: The Takeda Oncology Company.

Magnus Bjorkholm, MD
Shire, Wyeth Pharmaceuticals, Pfizer Inc.

Christian Buske, MD
Roche Pharmaceuticals.

Christine Chen, MD
Celgene Corporation, Ortho-Biotech.

Meletios Dimopoulos, MD
Roche Pharmaceuticals.

Morie Gertz, MD
Celgene Corporation, Millennium: The Takeda Oncology Company.

Irene Ghobrial, MD
Celgene Corporation, Millennium: The Takeda Oncology Company.

Douglas Joshua, MD
Janssen-Cilag, Celgene Corporation, Johnson & Johnson.

Robert A. Kyle, MD

Todd Levine, MD
Forest Laboratories, Pfizer Inc., Eli Lilly & Company, GlaxoSmithKline.

Nikhil Munshi, MD
Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Inc.
Marvin Stone, MD, MACP  
US Oncology.

Owen O’Connor, MD, PhD  

Steven P. Treon MD, PhD  
Celgene Corporation, Millennium: The Takeda Oncology Company, Genentech Inc, Biogen IDEC Inc.

Unapproved or Investigational Uses of Drugs and Devices.

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the FDA and/or the EMA. Participants are encouraged to consult the approved product labeling for any drug or device mentioned in this activity before its use. The opinions expressed in the workshop presentations are those of the abstract authors and do not necessarily represent the opinions of the IWWM5.